Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $9.29 Average PT from Analysts

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has been given a consensus rating of “Hold” by the nine analysts that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation and three have given a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $9.29.

NMRA has been the subject of a number of analyst reports. Bank of America reiterated an “underperform” rating and set a $1.00 price objective (down from $7.00) on shares of Neumora Therapeutics in a report on Wednesday, April 2nd. William Blair cut shares of Neumora Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, March 10th. Guggenheim cut shares of Neumora Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, March 7th. Needham & Company LLC reiterated a “buy” rating and set a $5.00 price objective on shares of Neumora Therapeutics in a report on Tuesday, May 13th. Finally, HC Wainwright reduced their price objective on shares of Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, March 4th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC purchased a new position in Neumora Therapeutics in the first quarter valued at about $463,000. Graham Capital Management L.P. raised its position in shares of Neumora Therapeutics by 1,643.7% in the first quarter. Graham Capital Management L.P. now owns 1,162,499 shares of the company’s stock valued at $1,162,000 after purchasing an additional 1,095,830 shares during the period. Jump Financial LLC bought a new stake in shares of Neumora Therapeutics in the first quarter valued at approximately $25,000. Nuveen LLC bought a new stake in shares of Neumora Therapeutics in the first quarter valued at approximately $221,000. Finally, Aigen Investment Management LP bought a new stake in shares of Neumora Therapeutics in the first quarter valued at approximately $36,000. 47.65% of the stock is currently owned by hedge funds and other institutional investors.

Neumora Therapeutics Trading Down 5.3%

NMRA opened at $0.76 on Thursday. Neumora Therapeutics has a 1-year low of $0.61 and a 1-year high of $17.19. The company has a market cap of $122.43 million, a P/E ratio of -0.47 and a beta of 2.73. The company has a fifty day moving average price of $0.76 and a two-hundred day moving average price of $2.22.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.02). On average, research analysts forecast that Neumora Therapeutics will post -1.61 EPS for the current fiscal year.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.